HRP20140768T1 - Antagonisti perifernih opioidnih receptora i njihove primjene - Google Patents
Antagonisti perifernih opioidnih receptora i njihove primjene Download PDFInfo
- Publication number
- HRP20140768T1 HRP20140768T1 HRP20140768AT HRP20140768T HRP20140768T1 HR P20140768 T1 HRP20140768 T1 HR P20140768T1 HR P20140768A T HRP20140768A T HR P20140768AT HR P20140768 T HRP20140768 T HR P20140768T HR P20140768 T1 HRP20140768 T1 HR P20140768T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutical preparation
- image
- formula
- use according
- Prior art date
Links
- 229940079358 peripheral opioid receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims 17
- 150000001450 anions Chemical class 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000007848 Bronsted acid Substances 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005070 sphincter Anatomy 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical group OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical group OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010013954 Dysphoria Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010052405 Gastric hypomotility Diseases 0.000 claims 1
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 150000001649 bromium compounds Chemical group 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 229910000039 hydrogen halide Inorganic materials 0.000 claims 1
- 239000012433 hydrogen halide Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical group OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 230000008991 intestinal motility Effects 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical group OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 1
- -1 methysulfonate Chemical compound 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (20)
1. Farmaceutski pripravak koji sadrži jedan spoj formule I:
[image]
gdje:
R1 i R2 svaki nezavisno predstavlja C1-6 alifatski; a
X- je neki prikladni anion;
te neki farmaceutski prihvatljivi nosač, adjuvant ili pomoćno sredstvo.
2. Spoj formule I:
[image]
gdje:
R1 i R2 svaki nezavisno predstavlja C1-6 alifatski; a
X- je neki prikladni anion, naznačen time da se taj spoj primjenjuje u terapiji.
3. Farmaceutski pripravak prema zahtjevu 1 ili spoj za primjenu prema zahtjevu 2, naznačen time da je X anion neke prikladne Brønstedove kiseline.
4. Farmaceutski pripravak ili spoj za primjenu za primjenu prema zahtjevu 3, naznačen time da je ta Brønstedova kiselina vodikov halid, karboksilna kiselina, sulfonska kiselina, sumporna kiselina ili fosforna kiselina.
5. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 3, naznačen time da je X- klorid, bromid, jodid, fluorid, bisulfat, tartrat, nitrat, citrat, bitartrat, karbonat, fosfat, malat, maleat, fumarat sulfonat, metisulfonat, format, karboksilat, sulfat, metilsulfat ili sukcinat.
6. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 5, naznačen time da je X- bromid.
7. Farmaceutski pripravak prema zahtjevu 1, ili spoj za primjenu prema zahtjevu 2, naznačen time da je R1 C1-4 alifatski a R2 je niži alkil.
8. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 7, naznačen time da je R1 neka (cikloalkil)alkil skupina ili alkenil skupina.
9. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 8, naznačen time da je R1 ciklopropil metil ili alil a R2 je metil.
10. Farmaceutski pripravak prema zahtjevu 1, ili spoj za primjenu prema zahtjevu 2, naznačen time da spomenuti spoj ima formulu II:
[image]
a X- je neki prikladni anion.
11. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 10, naznačen time je spomenuti spoj jedan spoj čija je formula II-1 ili II-2:
[image]
12. Pripravak koji sadrži spoj formule III:
[image]
naznačen time da je A- neki prikladni anion,
i barem jedan spoj formule I:
[image]
naznačen time da:
R1 i R2 svaki nezavisno predstavlja C1-6 alifatski; a
X- je neki prikladni anion.
13. Pripravak prema zahtjevu 12, naznačen time da je spoj prema formuli III spoj III-1:
[image]
a spoj prema formuli I je spoj II-1:
[image]
14. Farmaceutski pripravak koji sadrži pripravak prema zahtjevu 12 ili 13, i neki farmaceutski prihvatljivi nosač, adjuvant ili pomoćno sredstvo.
15. Farmaceutski pripravak prema bilo kojem od zahtjeva 1, 3-11, 14 i 15, koji nadalje sadrži neko dodatno terapeutsko sredstvo.
16. Farmaceutski pripravak prema bilo kojem od zahtjeva 1, 3-11, 14 i 15, za primjenu u terapiji.
17. Farmaceutski pripravak prema bilo kojem od zahtjeva 1, 3-11, 14 i 15, za primjenu radi smanjivanja barem jedne nuspojave opioidne terapije kod osobe koja se liječi opioidima.
18. Farmaceutski pripravak prema zahtjevu 17, naznačen time da dotična osoba pati od nekog poremećaja izazvanog, posredovanog ili pogoršanog djelovanjem opioidnih receptora.
19. Farmaceutski pripravak prema zahtjevu 17, naznačen time da ta nuspojava liječenja uključuje barem jednu pojavu iz skupine koju čine inhibicija intestinalnog motiliteta, gastrointestinalna disfunkcija, zatvor, hipomotilitet crijeva, začepljenje, hipomotilitet želuca, konstrikcija GI sfinktera, povećani tonus sfinktera, inhibicija gastrointestintestinalnog motiliteta, inhibicija pražnjenja želuca, odgođeno pražnjenje želuca, nepotpuno pražnjenje, mučnina, povraćanje, rumenilo kože, nadutost, abdominalna distenzija, disforija, svrbež i urinarna retencija.
20. Farmaceutski pripravak prema zahtjevu 19, naznačen time da je dotična osoba pacijent koji prima kratkoročnu terapiju opioidima ili pacijent koji prima kroničnu terapiju opioidima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92072207P | 2007-03-29 | 2007-03-29 | |
| PCT/US2008/058729 WO2008121860A1 (en) | 2007-03-29 | 2008-03-28 | Peripheral opioid receptor and antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140768T1 true HRP20140768T1 (hr) | 2014-11-21 |
Family
ID=39577863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140768AT HRP20140768T1 (hr) | 2007-03-29 | 2014-08-14 | Antagonisti perifernih opioidnih receptora i njihove primjene |
| HRP20150661TT HRP20150661T1 (en) | 2007-03-29 | 2015-06-18 | Peripheral opioid receptor and antagonists and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150661TT HRP20150661T1 (en) | 2007-03-29 | 2015-06-18 | Peripheral opioid receptor and antagonists and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8338446B2 (hr) |
| EP (2) | EP2139890B1 (hr) |
| JP (1) | JP5469593B2 (hr) |
| CA (1) | CA2682550C (hr) |
| DK (2) | DK2565195T3 (hr) |
| ES (2) | ES2540551T3 (hr) |
| HK (1) | HK1182694A1 (hr) |
| HR (2) | HRP20140768T1 (hr) |
| HU (1) | HUE025662T2 (hr) |
| MX (2) | MX2009010515A (hr) |
| PL (2) | PL2139890T3 (hr) |
| PT (2) | PT2139890E (hr) |
| SI (2) | SI2139890T1 (hr) |
| WO (1) | WO2008121860A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| SI2368553T1 (sl) | 2003-04-08 | 2015-05-29 | Progenics Pharmaceuticals, Inc. | Farmacevtske formulacije, vsebujoče metilnatrekson |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TW200815451A (en) | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| EP3064503A1 (en) * | 2007-03-29 | 2016-09-07 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| CA2713568C (en) * | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| AU2016201221B2 (en) * | 2008-09-30 | 2017-08-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| AU2013203119B2 (en) * | 2008-09-30 | 2015-12-03 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| NZ601595A (en) | 2010-03-11 | 2015-01-30 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
Family Cites Families (247)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1420015B1 (de) * | 1959-10-16 | 1971-08-26 | Boehringer Sohn Ingelheim | 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane |
| GB1202148A (en) | 1968-03-06 | 1970-08-12 | Sankyo Co | Pharmaceutical compositions |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3884916A (en) * | 1971-03-30 | 1975-05-20 | Janssen Pharmaceutica Nv | 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides |
| US3714159A (en) * | 1971-03-30 | 1973-01-30 | Janssen Pharmaceutica Nv | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides |
| US4326074A (en) * | 1972-09-22 | 1982-04-20 | William H. Rorer, Inc. | Amidinoureas |
| US4025652A (en) * | 1975-03-31 | 1977-05-24 | William H. Rorer, Inc. | Amidinoureas |
| US3937801A (en) * | 1973-07-10 | 1976-02-10 | American Home Products Corporation | Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs |
| US4060635A (en) | 1975-03-31 | 1977-11-29 | William H. Rorer, Inc. | Amidinoureas for treating diarrhea |
| US4203920A (en) * | 1975-03-31 | 1980-05-20 | William H. Rorer, Inc. | Amidinoureas |
| US4072686A (en) * | 1975-04-16 | 1978-02-07 | G. D. Searle & Co. | 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols |
| US4066654A (en) * | 1975-04-16 | 1978-01-03 | G. D. Searle & Co. | 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives |
| US3996214A (en) | 1976-02-23 | 1976-12-07 | G. D. Searle & Co. | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto |
| US4013668A (en) * | 1976-03-10 | 1977-03-22 | G. D. Searle & Co. | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds |
| US4012393A (en) * | 1976-03-22 | 1977-03-15 | G. D. Searle & Co. | 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5 |
| US4115400A (en) | 1976-05-27 | 1978-09-19 | Eli Lilly And Company | 1-Azoniabicyclo[3.1.0]hexanes |
| GB1593191A (en) | 1977-03-23 | 1981-07-15 | Reckitt & Colmann Prod Ltd | Derivatives of morphine |
| US4125531A (en) | 1977-04-18 | 1978-11-14 | G. D. Searle & Co. | 2-Substituted-1-azabicyclo[2.2.2]octanes |
| US4069223A (en) * | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
| US4116963A (en) | 1977-05-23 | 1978-09-26 | G.D. Searle & Co. | 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds |
| US4194045A (en) * | 1977-12-27 | 1980-03-18 | G. D. Searle & Co. | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| US4311833A (en) * | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
| US4277605A (en) | 1980-03-07 | 1981-07-07 | Bristol-Myers Company | Chemical compounds |
| US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4466968A (en) | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
| US4427676A (en) * | 1980-12-19 | 1984-01-24 | John Wyeth & Brother Ltd. | Thiomorpholine derivatives |
| US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| WO1983003197A1 (en) | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
| US4870084A (en) | 1982-03-16 | 1989-09-26 | Pfizer Inc. | Bicyclic benzo fused pyran compounds used for nausea treatment and prevention |
| US4430327A (en) * | 1982-05-18 | 1984-02-07 | Eli Lilly And Company | Method for treating pregnant females for pain and anxiety |
| US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4533739A (en) | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4462839A (en) | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
| US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
| US4666716A (en) | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| JPS6229515A (ja) | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
| JPH0676314B2 (ja) | 1985-09-30 | 1994-09-28 | 花王株式会社 | 坐剤基剤及び坐剤 |
| US4824853A (en) * | 1985-10-11 | 1989-04-25 | Janssen Pharmaceutica N.V. | α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea |
| US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
| US4806556A (en) * | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
| US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| DE3609073C2 (de) | 1986-03-18 | 1995-08-10 | Hans J Prof Dr Rer Nat Schmitt | Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten |
| US4990521A (en) * | 1986-07-03 | 1991-02-05 | Janssen Pharmaceutica | 4-(aroylamino)piperidine-butanimide derivatives |
| US5597564A (en) * | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
| JP2593501B2 (ja) | 1986-08-28 | 1997-03-26 | コーテクス・リミテッド | 動物成長促進剤 |
| US4888346A (en) | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
| US4765978A (en) | 1986-12-16 | 1988-08-23 | Schering Corporation | Novel vaginal suppository |
| FR2609632B1 (fr) | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
| NL8700842A (hr) | 1987-04-10 | 1988-11-01 | Duphar Int Res | |
| US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| US4857833A (en) | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
| CA1315689C (en) | 1987-09-03 | 1993-04-06 | Leon I. Goldberg | Quarternary derivatives of noroxymorphone which relieve nausea and emesis |
| ES2051742T3 (es) | 1987-09-10 | 1994-07-01 | Univ Chicago | Derivados cuaternarios de noroxi-morfina que mitigan las nauseas y la emesis. |
| US4912114A (en) * | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
| EP0350221B1 (en) * | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same |
| EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4999342A (en) * | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
| US4857533A (en) | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
| US4863928A (en) | 1989-01-04 | 1989-09-05 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for arthritic and inflammatory diseases |
| US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5116868A (en) | 1989-05-03 | 1992-05-26 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US4965269A (en) | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| US5236947A (en) | 1990-02-28 | 1993-08-17 | Jouveinal S.A. | Propanamines, their pharmacological properties and their application as an antidiarrheal |
| ES2097208T3 (es) | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
| JPH04230625A (ja) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
| ES2148174T3 (es) | 1991-02-25 | 2000-10-16 | Univ Boston | Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. |
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| CA2064373C (en) | 1991-03-29 | 2005-08-23 | Buddy Eugene Cantrell | Piperidine derivatives |
| US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| US5220017A (en) | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| DK0590060T3 (da) * | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5614219A (en) * | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
| US5256154A (en) | 1992-01-31 | 1993-10-26 | Sterling Winthrop, Inc. | Pre-filled plastic syringes and containers and method of terminal sterilization thereof |
| GB2272375B (en) | 1992-04-10 | 1996-02-14 | Vnii Med Polimerov | Pharmaceutical composition |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
| ES2095001T5 (es) * | 1992-12-22 | 2001-03-16 | Univ Cincinnati | Una composicion terapeutica administrable oralmente y su metodo de obtencion. |
| DE4303214A1 (de) | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
| US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
| US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5391372A (en) * | 1993-06-28 | 1995-02-21 | Campbell; Elizabeth | Methods of treating colic and founder in horses |
| WO1995003308A1 (en) | 1993-07-23 | 1995-02-02 | Toray Industries, Inc. | Morphinan derivative and medicinal use |
| GB2281205A (en) | 1993-08-24 | 1995-03-01 | Euro Celtique Sa | Oral opioid analgesic |
| DE69415643T2 (de) * | 1993-11-05 | 1999-06-17 | Shin-Etsu Chemical Co., Ltd., Tokio/Tokyo | Härtbare Harzzusammensetzungen |
| SE9303744D0 (sv) * | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
| US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| WO1995030774A1 (en) | 1994-05-05 | 1995-11-16 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| IT1269826B (it) | 1994-05-24 | 1997-04-15 | Paolo Minoia | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate |
| US5536507A (en) | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
| US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| US5614222A (en) * | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| US6096763A (en) | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
| US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
| US5804595A (en) | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
| IL119819A (en) | 1995-12-21 | 2004-07-25 | Syngenta Participations Ag | Processes for the preparation of derivatives of acid 3 - amino - 2 - Mercaptobenzoic, their use in the preparation of microbial and plant-killing agents and a number of such new compounds |
| AU1767997A (en) | 1996-02-15 | 1997-09-02 | Janssen Pharmaceutica N.V. | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| ATE211906T1 (de) * | 1996-03-12 | 2002-02-15 | Alza Corp | Zusammensetzung und dosisform mit einem opioid- antagonisten |
| US6136780A (en) | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
| US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US20010036469A1 (en) | 1997-01-13 | 2001-11-01 | Gooberman Lance L. | Opiate antagonist implant and process for preparation therefor |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| HU9701081D0 (en) * | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
| US6525038B1 (en) * | 1997-06-24 | 2003-02-25 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
| US6353004B1 (en) * | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
| US6096764A (en) | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| US6099853A (en) | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| AU2003204844B2 (en) | 1997-11-03 | 2007-06-07 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
| PT1685839E (pt) | 1997-12-22 | 2013-07-08 | Euro Celtique Sa | Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide |
| EP0930334A1 (en) | 1998-01-16 | 1999-07-21 | Quest International B.V. | Polysaccharide conjugate capable of binding cellulose |
| GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| ATE328599T1 (de) * | 1998-04-03 | 2006-06-15 | Ajinomoto Kk | Antitumorale mittel |
| US6359111B1 (en) * | 1998-05-28 | 2002-03-19 | Neorx Corporation | Opioid receptor targeting |
| HN1999000149A (es) * | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| US20010010919A1 (en) | 1998-10-13 | 2001-08-02 | David K. Grandy | Opioid antagonists and methods of their use |
| US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| US7129265B2 (en) | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
| US6171620B1 (en) | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US20020068712A1 (en) | 1999-07-23 | 2002-06-06 | Troy Stevens | Use of decreasing levels of functional transient receptor potential gene product |
| US20030105121A1 (en) | 1999-07-27 | 2003-06-05 | Bernard Bihari | Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents |
| CA2380524A1 (en) | 1999-08-25 | 2001-03-01 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
| CN1202815C (zh) | 1999-08-31 | 2005-05-25 | 格吕伦塔尔有限公司 | 含有曲马朵糖精盐的持续释放给药剂型 |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| WO2001032180A2 (en) | 1999-11-01 | 2001-05-10 | Rodeva Limited | Composition for treatment of constipation and irritable bowel syndrome |
| ES2251168T3 (es) * | 1999-11-04 | 2006-04-16 | Institut Gustave Roussy | Agente antiviral en combinacion con radioterapia para el tratamiento del cancer. |
| AU4136901A (en) | 1999-11-29 | 2001-06-18 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| CA2392362A1 (en) | 1999-11-29 | 2001-05-31 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| US6384044B1 (en) | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| WO2001042207A2 (en) | 1999-11-29 | 2001-06-14 | Adolor Corporation | Novel methods for the treatment and prevention of ileus |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US20010046968A1 (en) | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
| US6967075B2 (en) | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
| JP2004515455A (ja) | 2000-05-05 | 2004-05-27 | ペイン・セラピューティクス・インコーポレイテッド | オピオイドアンタゴニスト組成物および投薬形態 |
| ATE440618T1 (de) * | 2000-06-22 | 2009-09-15 | Univ Iowa Res Found | Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs. |
| EP1175905A1 (en) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
| FI116089B (sv) * | 2000-07-27 | 2005-09-15 | Johan Tore Karlstroem | Anordning och förfaranden vid reglar |
| RU2241462C2 (ru) | 2000-07-28 | 2004-12-10 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция |
| NZ507152A (en) * | 2000-09-27 | 2001-06-29 | Hiltive Pty Ltd | Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members |
| AU2002249885A1 (en) | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
| DK1229130T3 (en) | 2000-12-04 | 2014-02-24 | Primagen B V | TEST BASED ON nucleic acids OF ENDOSYMBIONTISKE, cellular organelles |
| WO2002047716A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| MXPA03008623A (es) | 2001-03-23 | 2004-05-21 | Shire Biochem Inc | Combinacion farmaceutica para el tratamiento del cancer. |
| US20040242523A1 (en) | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| US20040136908A1 (en) | 2001-04-09 | 2004-07-15 | Olson William C. | Anti-cd19 immunotoxins |
| US20030039689A1 (en) * | 2001-04-26 | 2003-02-27 | Jianbing Chen | Polymer-based, sustained release drug delivery system |
| EP1404323B1 (en) | 2001-06-05 | 2009-10-28 | The University of Chicago | Use of methylnaltrexone to treat immune suppression |
| CA2463733C (en) | 2001-08-31 | 2011-03-22 | Eugene A. Woltering | Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice (morinda citrifolia) |
| LT1436012T (lt) | 2001-10-18 | 2018-04-10 | Nektar Therapeutics | Opioidų antagonistų polimerų konjugatai |
| US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| WO2003037365A1 (en) * | 2001-11-01 | 2003-05-08 | The Johns Hopkins University | Methods and compositions for treating vascular leak using hepatocyte growth factor |
| JP4357965B2 (ja) * | 2001-12-21 | 2009-11-04 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター |
| US20050011468A1 (en) * | 2002-02-04 | 2005-01-20 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| CA2475305A1 (en) | 2002-02-04 | 2004-02-19 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
| MXPA04008772A (es) | 2002-03-14 | 2004-12-06 | Euro Celtique Sa | Composiciones de clorhidrato de naltrexona. |
| US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| US7355081B2 (en) | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| EP1515754B1 (en) | 2002-05-17 | 2011-05-25 | Board Of Regents, The University Of Texas System | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| US7012100B1 (en) * | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
| US20040010997A1 (en) * | 2002-07-17 | 2004-01-22 | Oren Close | Guides to align masonry walls defining apertures, and methods of use |
| US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| US7691374B2 (en) * | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| WO2004043964A2 (en) | 2002-11-08 | 2004-05-27 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
| AU2003296954A1 (en) | 2002-12-13 | 2004-07-09 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
| WO2004054569A1 (en) * | 2002-12-16 | 2004-07-01 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| RU2373936C2 (ru) * | 2003-04-08 | 2009-11-27 | Проджиникс Фармасьютикалз, Инк. | Применение метилналтрексона для лечения синдрома раздраженного кишечника |
| SI2368553T1 (sl) | 2003-04-08 | 2015-05-29 | Progenics Pharmaceuticals, Inc. | Farmacevtske formulacije, vsebujoče metilnatrekson |
| JP2006522819A (ja) | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法 |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
| US20070010450A1 (en) * | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
| US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| AU2003903387A0 (en) | 2003-07-02 | 2003-07-17 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
| US20050028825A1 (en) * | 2003-07-15 | 2005-02-10 | Mccoy Leonard | Condom cover all |
| EP1682006A4 (en) | 2003-10-29 | 2011-01-26 | Physiosonics Inc | METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| US20070082044A1 (en) * | 2004-03-10 | 2007-04-12 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
| TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| US6946556B1 (en) | 2004-05-21 | 2005-09-20 | Acura Pharmaceuticals, Inc. | Preparation of opioid analgesics by a one-pot process |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| US7388008B2 (en) * | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2006039705A2 (en) | 2004-09-30 | 2006-04-13 | Becton, Dickinson And Company | Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith |
| WO2006078842A1 (en) | 2005-01-20 | 2006-07-27 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| ES2714198T3 (es) | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| US20080194611A1 (en) | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| WO2007053194A2 (en) | 2005-06-03 | 2007-05-10 | The University Of Chicago | Modulation of cell barrier dysfunction |
| CA2610951A1 (en) | 2005-06-03 | 2006-12-14 | The University Of Chicago | Modulation of microbial pathogen-host cell interactions |
| AU2006258060A1 (en) | 2005-06-09 | 2006-12-21 | Mallinckrodt Inc. | Method for separation and purification of naltrexone by preparative chromatography |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| CA2627158A1 (en) * | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2receptor antagonist |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| US20080069871A1 (en) * | 2006-07-21 | 2008-03-20 | Vaughn Jason M | Hydrophobic abuse deterrent delivery system |
| TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200815451A (en) | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| CA2670386A1 (en) | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers |
| MX2009005461A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | N-oxidos de analogos de 4,5-epoxi-morfinano. |
| MX2009005455A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano. |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| EP3064503A1 (en) | 2007-03-29 | 2016-09-07 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
-
2008
- 2008-03-28 PT PT87446597T patent/PT2139890E/pt unknown
- 2008-03-28 PL PL08744659T patent/PL2139890T3/pl unknown
- 2008-03-28 WO PCT/US2008/058729 patent/WO2008121860A1/en active Application Filing
- 2008-03-28 EP EP08744659.7A patent/EP2139890B1/en not_active Not-in-force
- 2008-03-28 MX MX2009010515A patent/MX2009010515A/es active IP Right Grant
- 2008-03-28 CA CA2682550A patent/CA2682550C/en not_active Expired - Fee Related
- 2008-03-28 SI SI200831262T patent/SI2139890T1/sl unknown
- 2008-03-28 DK DK12182420.5T patent/DK2565195T3/en active
- 2008-03-28 PL PL12182420T patent/PL2565195T3/pl unknown
- 2008-03-28 JP JP2010501265A patent/JP5469593B2/ja not_active Expired - Fee Related
- 2008-03-28 PT PT121824205T patent/PT2565195E/pt unknown
- 2008-03-28 US US12/594,139 patent/US8338446B2/en not_active Expired - Fee Related
- 2008-03-28 HU HUE12182420A patent/HUE025662T2/en unknown
- 2008-03-28 SI SI200831447T patent/SI2565195T1/sl unknown
- 2008-03-28 ES ES12182420.5T patent/ES2540551T3/es active Active
- 2008-03-28 ES ES08744659.7T patent/ES2493590T3/es active Active
- 2008-03-28 EP EP20120182420 patent/EP2565195B1/en not_active Not-in-force
- 2008-03-28 DK DK08744659.7T patent/DK2139890T3/da active
-
2009
- 2009-09-29 MX MX2013006391A patent/MX336366B/es unknown
-
2012
- 2012-11-09 US US13/672,885 patent/US8772310B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 HK HK13109877.4A patent/HK1182694A1/xx not_active IP Right Cessation
-
2014
- 2014-08-14 HR HRP20140768AT patent/HRP20140768T1/hr unknown
-
2015
- 2015-06-18 HR HRP20150661TT patent/HRP20150661T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5469593B2 (ja) | 2014-04-16 |
| PT2565195E (pt) | 2015-07-28 |
| EP2565195B1 (en) | 2015-05-06 |
| DK2139890T3 (da) | 2014-08-25 |
| ES2540551T3 (es) | 2015-07-10 |
| EP2139890B1 (en) | 2014-06-25 |
| HRP20150661T1 (en) | 2015-09-25 |
| EP2565195A1 (en) | 2013-03-06 |
| SI2565195T1 (sl) | 2015-09-30 |
| MX2009010515A (es) | 2009-10-19 |
| PT2139890E (pt) | 2014-09-03 |
| US8338446B2 (en) | 2012-12-25 |
| WO2008121860A9 (en) | 2009-11-12 |
| MX336366B (es) | 2016-01-18 |
| CA2682550C (en) | 2016-05-17 |
| EP2139890A1 (en) | 2010-01-06 |
| US8772310B2 (en) | 2014-07-08 |
| JP2010522771A (ja) | 2010-07-08 |
| PL2565195T3 (pl) | 2015-10-30 |
| ES2493590T3 (es) | 2014-09-12 |
| PL2139890T3 (pl) | 2014-11-28 |
| WO2008121860A1 (en) | 2008-10-09 |
| SI2139890T1 (sl) | 2014-12-31 |
| CA2682550A1 (en) | 2008-10-09 |
| DK2565195T3 (en) | 2015-06-29 |
| HK1182694A1 (en) | 2013-12-06 |
| US20130281483A1 (en) | 2013-10-24 |
| HUE025662T2 (en) | 2016-04-28 |
| US20100099699A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140768T1 (hr) | Antagonisti perifernih opioidnih receptora i njihove primjene | |
| WO1998023290A1 (fr) | Agent antiprurigineux | |
| CN107787323B (zh) | 用于抑制shp2活性的化合物和组合物 | |
| JP2011190259A5 (hr) | ||
| JP4882744B2 (ja) | 止痒剤 | |
| HRP20110775T1 (hr) | Oblik doziranja koji sadrži oksikodon i nalokson | |
| JP5461386B2 (ja) | 末梢オピオイド受容体アンタゴニストおよびその使用 | |
| CN107922388A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| JP2010510325A (ja) | ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体の（ｓ）−ｎ−立体異性体 | |
| AU2007323571A1 (en) | (R)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs | |
| CN102918039A (zh) | 甲基纳曲酮的口服制剂和亲脂盐 | |
| US10167295B2 (en) | Analgesic compounds and methods of use | |
| JP2009533343A5 (hr) | ||
| JP2006519852A5 (hr) | ||
| JP2020011996A (ja) | ｐ−置換非対称尿素及びその医薬的使用 | |
| NZ604417A (en) | Liquid nasal spray containing low-dose naltrexone | |
| JP2013506004A5 (hr) | ||
| JP2015514743A5 (hr) | ||
| JP2008543957A5 (hr) | ||
| CN101360491A (zh) | 5－ht4激动剂与胆碱酯酶抑制剂的组合 | |
| TW490465B (en) | Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof | |
| CA2594987A1 (en) | Therapeutic agent for constipation | |
| ES2733905T3 (es) | Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol | |
| JP2008521874A5 (hr) | ||
| JP2010518173A5 (hr) |